Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 802 results for "eisai"

Eisai Launches
Sys-Con Italia

Eisai Launches "Search for the Next Medikidz Star" Contest for...

Winner to be Featured in Third Book of Epilepsy Education Comic Book Series WOODCLIFF LAKE, N.J., Oct. 24, 2014 /PRNewswire/ -- Eisai Inc., a leader in the epilepsy community, announces the launch of the "Search for the Next Medikidz Star," a ... Scottrade, 23 hours ago
[x]  

19 images for eisai

BioSpace, 4 days ago
Pharma Letter, 4 days ago
BioSpace, 17 hours ago
Securities Technology Monitor, 23 hours ago
BioSpace, 1 week ago
Pharma Letter, 1 week ago
Motley Fool, 2 days ago
PR Newswire, 4 days ago
Drug Discovery and Development, 1 week ago
Pharma Letter, 1 week ago

Eisai : Gets FDA Approval of sNDA for Rufinamide

Eisai recently reported that the U.S. Food and Drug Administration accepted the company's sNDA for rufinamide and granted it priority review designation as an adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric ...
 4 Traders4 hours ago Eisai Secures FDA Approval of sNDA for Rufinamide  Individual.com1 week ago EISAI : Secures FDA Approval of sNDA for Rufinamide  4 Traders1 week ago

Eisai Introduces Metastatic Breast Cancer Resource

Eisai has reported the launch of an online portal designed to provide resources for women with metastatic breast cancer. "Today is Metastatic Breast Cancer Awareness Day, an important time to recognize an overlooked group of patients who live with a ...
 Individual.com1 week ago Eisai Introduces New Online Resource: mbcInfoCenter.com  Individual.com1 week ago

Hikma partners with Eisai for distribution of anti-epileptic drug

Hikma Pharmaceuticals PLC, a developer of generic and in-licensed pharmaceutical products, has announced a partnership with Eisai Co., Ltd., a provider of drugs for over-the-counter and diagnostic uses, for the distribution of Fycompa, or ...
 Individual.com1 week ago BRIEF-Hikma Pharma says in partnership with Eisai for epilepsy treatment drug  Reuters1 week ago

Eisai announces launch of Halaven in Australia

Eisai Australia Pty. Ltd., a pharmaceutical sales subsidiary of Eisai Co., Ltd., has launched Halaven eribulin mesylate in Australia. Halaven is an anticancer agent discovered and developed by Eisai. It is currently approved in more than 55 ...
 Individual.com2 weeks ago
EWeek

Merck and Pfizer join Accenture's Life Sciences Cloud Coalition

Accenture ($ACN) has joined with some big names for its R&D analytics platform. Eisai, Merck ($MRK) and Pfizer ($PFE) have signed up to collaborate on further development of the system, which is built on a mix of technologies from Accenture and ...
 Fierce Biotech IT1 week ago Leading Pharma Companies Help Shape New Accenture Life Sciences Cloud for R  Fierce Biotech IT1 week ago Accenture, Oracle Partner on Life Sciences Cloud for R  EWeek4 days ago R&D success is in the cloud  Pharma Letter1 week ago
[x]  

Hikma to distribute Eisai's epilepsy treatment Fycompa in Middle East

UK-based Hikma Pharmaceuticals has entered into a five-year partnership to distribute Eisai's first-in-class epilepsy treatment, Fycompa (perampanel), in the Middle East. Perampanel is used as an adjunctive treatment of partial onset seizures, with ...
 Pharmaceutical Business Review1 week ago Hikma to market Eisai's epilepsy treatment Fycompa in Middle East  Pharmaceutical Technology1 week ago

Eisai Names Partner For Pan Middle East Distribution of First-in-class Epilepsy Treatment Fycompa® (perampanel)

PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS Fycompa® (perampanel), Eisai's first-in-class epilepsy treatment, will be made available throughout the Middle East "We are very pleased to announce the partnership with Hikma, who ...
 ADVFN UK1 week ago
[x]  

French Transparency Commission recognizes efficacy of Eisai's Zonegran monotherapy

Transparency advice for Japanese pharma major Eisai's (TYO: 4523) Zonegran (zonisamide) monotherapy in the treatment of partial seizures, with or without secondary generalization, in adults with newly-diagnosed epilepsy, has been published by the ...
 Pharma Letter2 weeks ago Long-Term Safety and Efficacy of Once-Daily Zonegran┬« (zonisamide) Monotherapy Demonstrated in Extension of Pivotal Study  Sys-Con Canada3 days ago
[x]  

EISAI : SUPPORTS CYCLONE RELIEF EFFORTS IN ANDHRA PRADESH, INDIA

Release date- 23102014 - Eisai expresses its heartfelt sympathies to all those affected by the recent cyclone which struck the state of Andhra Pradesh in India . Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , ' Eisai ') announced today ...
 4 Traders23 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less